Management of Acquired Factor X Deficiency Caused by In Vitro Non-neutralizing Anti-factor X Autoantibodies with Pre-emptive Corticosteroid Therapy.
Intern Med
; 62(16): 2401-2406, 2023.
Article
de En
| MEDLINE
| ID: mdl-37587057
ABSTRACT
Coagulation factor X (FX) deficiency causes severe hemorrhagic symptoms. We herein report a 90-year-old man with hemorrhagic symptoms and prolongation of prothrombin time (PT) and activated partial thromboplastin time (APTT). Cross-mixing tests showed a factor deficiency pattern, but administration of plasma products was not effective. Acquired coagulation factor deficiency was suspected, and immunosuppressive therapy was started. After the intervention, his hemorrhagic symptoms improved. A decrease in FX activity was later confirmed, and anti-FX autoantibody was retrospectively detected by an enzyme-linked immunosorbent assay. Immediate intervention is important for patients suspected of having acquired coagulation factor deficiency.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Déficit en facteur X
Type d'étude:
Observational_studies
Limites:
Aged80
/
Humans
/
Male
Langue:
En
Journal:
Intern Med
Sujet du journal:
MEDICINA INTERNA
Année:
2023
Type de document:
Article
Pays d'affiliation:
Japon